Payment overview · 2025
General Payments
$36.52
2 reported records · 2 companies
Healthcare provider profile · identity verified
James David Wilson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SOMERSET, KY · NPI 1225002561
Verified facts
What the public records show
CMS Open Payments records show James David Wilson, M.D. received $36.52 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 53.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.48 | 53.3% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $17.04 | 46.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $36.52 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 459 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 75 |
| Gabapentin | Gabapentin | 387 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 367 | 78 |
| Omeprazole | Omeprazole | 357 | 76 |
| Metformin Hcl Er | Metformin Hcl | 331 | 70 |
| Montelukast Sodium | Montelukast Sodium | 273 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 270 | 59 |
| Furosemide | Furosemide | 250 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 242 | 59 |
| Tramadol Hcl | Tramadol Hcl | 229 | 36 |
| Lisinopril | Lisinopril | 219 | 45 |
| Famotidine | Famotidine | 202 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 197 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 184 | 29 |
| Losartan Potassium | Losartan Potassium | 165 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 27 |
| Glimepiride | Glimepiride | 152 | 32 |
| Clonazepam | Clonazepam | 150 | 19 |
| Simvastatin | Simvastatin | 145 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 31 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 140 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 29 |
| Diazepam | Diazepam | 112 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 101 | 17 |
| Ozempic | Semaglutide | 100 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 17 |
| Trazodone Hcl | Trazodone Hcl | 97 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 93 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 15 |
| Meloxicam | Meloxicam | 91 | 32 |
| Allopurinol | Allopurinol | 90 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 19 |
| Ezetimibe | Ezetimibe | 88 | 25 |
| Lorazepam | Lorazepam | 87 | 11 |
| Eliquis | Apixaban | 83 | 17 |
| Naproxen | Naproxen | 83 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 79 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 17 |
| Potassium Chloride | Potassium Chloride | 77 | 18 |
| Lovastatin | Lovastatin | 74 | 17 |
| Pregabalin | Pregabalin | 71 | 11 |
| Fenofibrate | Fenofibrate | 69 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 17 |
| Celecoxib | Celecoxib | 68 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 64 | 14 |
| Jardiance | Empagliflozin | 63 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 62 | suppressed |
| Januvia | Sitagliptin Phosphate | 57 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 14 |
| Mirtazapine | Mirtazapine | 55 | 17 |
| Prednisone | Prednisone | 54 | 47 |
| Donepezil Hcl | Donepezil Hcl | 53 | 18 |
| Vascepa | Icosapent Ethyl | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 42 |
| Linzess | Linaclotide | 48 | suppressed |
| Methylprednisolone | Methylprednisolone | 48 | 42 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 22 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Azithromycin | Azithromycin | 41 | 41 |
| Desloratadine | Desloratadine | 41 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Metformin Hcl | Metformin Hcl | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 36 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Fentanyl | Fentanyl | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Nadolol | Nadolol | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 12 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Nicotrol Ns | Nicotine | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 11 |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prevacid | Lansoprazole | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36.52 · 2 records | Novo Nordisk Inc | SUBLOCADE, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error